These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7715541)

  • 1. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
    Steinherz LJ; Steinherz PG; Tan C
    Med Pediatr Oncol; 1995 Jun; 24(6):352-61. PubMed ID: 7715541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
    Steinherz LJ; Steinherz PG; Tan CT; Heller G; Murphy ML
    JAMA; 1991 Sep; 266(12):1672-7. PubMed ID: 1886191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.
    Suzuki J; Yanagisawa A; Shigeyama T; Tsubota J; Yasumura T; Shimoyama K; Ishikawa K
    Angiology; 1999 Jan; 50(1):37-45. PubMed ID: 9924887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
    Elbl L; Hrstkova H; Tomaskova I; Michalek J
    Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.
    Schwartz CL; Hobbie WL; Truesdell S; Constine LC; Clark EB
    J Clin Oncol; 1993 Oct; 11(10):1906-10. PubMed ID: 8410117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late cardiotoxicity after treatment for a malignant bone tumor.
    Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
    Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term study of anthracycline-induced cardiomyopathy in children and adolescents].
    Koch H; Schmitz L; Brockmeier K; Hartmann R; Bein G; Henze G
    Klin Padiatr; 1991; 203(4):262-7. PubMed ID: 1942932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults.
    Larsen RL; Jakacki RI; Vetter VL; Meadows AT; Silber JH; Barber G
    Am J Cardiol; 1992 Jul; 70(1):73-7. PubMed ID: 1615874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
    Hauser M; Gibson BS; Wilson N
    Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer.
    Elbl L; Hrstkova H; Chaloupka V
    Eur J Pediatr; 2003 Oct; 162(10):690-6. PubMed ID: 12905011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy.
    Hashimoto I; Ichida F; Miura M; Okabe T; Kanegane H; Uese K; Hamamichi Y; Misaki T; Koizumi S; Miyawaki T
    Circulation; 1999 May; 99(18):2367-70. PubMed ID: 10318655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
    Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
    J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
    Bristow MR; Billingham ME; Mason JW; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular late potentials: another expression of cardiotoxicity of cytostatic drugs in children?
    Tamminga RY; Bink-Boelkens MT; Kievit J
    Int J Cardiol; 1992 Sep; 36(3):283-8. PubMed ID: 1428262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Echocardiography studies for detection of cardiotoxic side effects of anthracycline therapy in childhood].
    Richter R; Grumpelt U; Mittler U; Kluba U
    Monatsschr Kinderheilkd; 1990 Dec; 138(12):823-7. PubMed ID: 1965011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitral regurgitation after anthracycline treatment for childhood malignancy.
    Allen J; Thomson JD; Lewis IJ; Gibbs JL
    Heart; 2001 Apr; 85(4):430-2. PubMed ID: 11250971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.